Jiangsu Aotai Xin Biopharmaceutical Technology

Jiangsu Aotai Xin Biopharmaceutical Technology is a clinical-stage biotechnology company headquartered in Suzhou, China, specializing in the development of innovative small molecule therapeutics for cancer and autoimmune disorders. The company focuses on targeting challenging intracellular proteins involved in immune regulation and protein degradation pathways. Its lead program, ATX-101, is a highly selective HPK1 inhibitor designed to enhance anti-tumor immune responses and is currently in Phase 1 clinical development. Aotai Xin utilizes its proprietary discovery engine to build a robust pipeline of candidates, including USP7 inhibitors, aimed at addressing significant unmet medical needs in oncology. The company has successfully secured IND clearances from both the U.S. FDA and China's NMPA for its lead asset.